About Vial
Vial is a company based in San Francisco (United States) founded in 2020 by Simon Burns and Andrew Brackin. Vial has raised $67 million across 1 funding round from investors including General Catalyst, BoxGroup and Byers Capital. The company has 65 employees as of December 31, 2022. Vial operates in a competitive market with competitors including Javara Research, Alcanza Clinical Research, The START Center for Cancer Research, Global Coalition for Adaptive Research and LMC Manna Research, among others.
- Headquarter San Francisco, United States
- Employees 65 as on 31 Dec, 2022
- Founders Simon Burns, Andrew Brackin
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
$110.71 K (USD)23as on Dec 31, 2022
-
Net Profit
$50.01 K (USD)-27as on Dec 31, 2022
-
EBITDA
-
Total Equity Funding
$67 M (USD)
in 1 rounds
-
Latest Funding Round
$67 M (USD), Series B
Dec 01, 2022
-
Investors
General Catalyst
& 2 more
-
Employee Count
65
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Vial
Unlock access to complete
Funding Insights of Vial
Vial has successfully raised a total of $67M through 1 strategic funding round. The most recent funding activity was a Series B round of $67 million completed in December 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series B — $67.0M
-
First Round
First Round
(01 Dec 2022)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2022 | Amount | Series B - Vial | Valuation | General Catalyst |
Investors in Vial
Vial has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include General Catalyst, BoxGroup and Byers Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment and transformation services for entrepreneurs in technology and finance sectors.
|
Founded Year | Domain | Location | |
|
Investing in early-stage tech companies and ideas.
|
Founded Year | Domain | Location | |
|
Byers Capital is engaged in direct investments in technology and biotechnology.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Vial
Financial Statements - Vial
Vial Comparisons
Competitors of Vial
Vial operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Javara Research, Alcanza Clinical Research, The START Center for Cancer Research, Global Coalition for Adaptive Research and LMC Manna Research, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Clinical trials for pharmaceuticals are conducted across therapeutic areas.
|
|
| domain | founded_year | HQ Location |
Clinical research site network focused on accelerating the development of new therapies by reducing barriers to participation
|
|
| domain | founded_year | HQ Location |
Early-phase oncology clinical trials and research services are provided.
|
|
| domain | founded_year | HQ Location |
Nonprofit organization sponsors clinical trials for rare diseases worldwide.
|
|
| domain | founded_year | HQ Location |
Outpatient clinical trials are conducted at North American research sites.
|
Frequently Asked Questions about Vial
Vial was founded in 2020 and raised its 1st funding round 2 years after it was founded.
Vial is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Simon Burns is the current CEO of Vial. They have also founded this company.
Vial is a funded company, having raised a total of $67M across 1 funding round to date. The company's 1st funding round was a Series B of $67M, raised on Dec 01, 2022.
As of Dec 31, 2022, the latest employee count at Vial is 65.
Annual revenue of Vial is $110.71K as on Dec 31, 2022.
Vial was founded in 2020 and is headquartered in San Francisco, United States. Operations center on healthcare data capture, clinical trial management, and CRO services within the biotech sector. Clinical trials are overseen for sponsors through integrated technology platforms and teams experienced in clinical operations and technology. Full-service support is extended to streamline trial processes across various therapeutic areas.
Vial's top competitors include Javara Research, The START Center for Cancer Research and Summit Clinical Research.
Vial has 3 investors. Key investors include General Catalyst, BoxGroup, and Byers Capital.